[et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https://www.progeriaresearch.org/wp-content/uploads/2024/10/landscapelogos2000-x-1000-px.png” title_text=”landscapelogos(2000 x 1000 px)” url=”https://www.charitynavigator.org/ein/043460220″ align=”center” admin_label=”logos” _builder_version=”4.27.0″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”][/et_pb_image][et_pb_text _builder_version=”4.27.0″ text_font_size=”18px” background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]

We’re back at it! PRF is thrilled to announce the start of a new Progeria clinical trial with a new drug called Progerinin. PRF will help fund and coordinate this trial to determine whether a new drug, called Progerinin, plus the life-extending Progeria drug lonafarnib (Zokinvy) is more beneficial than lonafarnib alone.

This trial is a partnership between PRF, trial sponsor, Korean-based biotech company PRG Science & Technology (PRG S&T), Boston Children’s Hospital and Brigham and Women’s Hospital in Boston, MA, where the trial will take place. While lonafarnib has been shown to increase lifespan in a Progeria mouse model by 25%, Progerinin has been shown to increase the mice lifespan by 50%.Very encouraging!

For more details on the trial, check out our press release here.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]